Endothelin antagonistic substance

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

514 19, 530330, A61K 3800, C07K 500, C07K 508, C07K 510

Patent

active

056144989

ABSTRACT:
Peptides having the formula: ##STR1## inhibit the binding of endothelin to its ET.sub.B receptor and are useful in treating diseases associated with excess production or secretion of endothelin.

REFERENCES:
patent: 3872074 (1975-03-01), K onig et al.
patent: 5284828 (1994-02-01), Hemmi et al.
H. Koyama et al., "Plasma Endothelin Levels in Patients with Uraemia", The Lancet, May 6, 1989, pp. 991-992.
M. Sugiura et al., "Endotoxin Stimulates Endothelin-Release in Vivo and in Vitro as Determined by Radioimmunoassay", Biochemical and Biophysical Research Communications, Jun. 30, 1989, vol. 161, No. 3, 1989, pp. 1220-1227.
K. Tomita et al., "Plasma Endothelin Levels in Patients with Acute Renal Failure", vol. 321, No. 16, p. 1127.
A. Nomura et al., "Endothelin and Bronchial Asthma", The Lancet, Sep. 23, 1989, pp. 747-748.
P. Cernacek et al., "Immunoreactive Endothelin in Human Plasma: Marked Elevations in Patients in Cardiogenic Shock", Biochemical and Biophysical Research Communications, Jun. 15, 1989, vol. 161, No. 2, 1989, pp. 562-567.
H. Levesque et al., "Raised plasma endothelin in aneurysmal subarachnoid haemorrhage", The Lancet, Feb. 3, 1990, p. 290.
R. Suzuki et al., "The role of endothelin-1 in the origin of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage", J. Neurosurg., Jul., 1992, vol. 77, pp. 96-100.
Y. Hirata et al., "Plasma Endothelin Levels During Surgery", The New England Journal of Medicine, Dec. 14, 1989, p. 1686.
M. Onizuka et al., "Endothelin-1 mediates regional blood flow during and after pulmonary operations", The Journal of Thoracic and Cardiovascular Surgery, Dec., 1992, vol. 104, No. 6, pp. 1696-1701.
H. Chang et al., "Plasma Endothelin Levels and Surgically Correctable Pulmonary Hypertension", Ann. Thorac. Surg., 1993, vol. 55, pp. 450-458.
H. Komai et al., "Increased plasma levels of endothelin-1 after cardiopulmonary bypass in patients with pulmonary hypertension and congenital heart disease", The Journal of Thoracic and Cardiovascular Surgery, Sep., 1993, vol. 106, No. 3, pp. 473-478.
M. Shichiri et al., "Plasma Endothelin Levels in Hypertension and Chronic Renal Failure", Hypertension, May, 1990, vol. 15, No. 5, pp. 493-496.
M. Kohno et al., "Plasma Immunoreactive Endothelin in Essential Hypertension", The American Journal of Medicine, Jun. 1990, vol. 88, pp. 614-618.
M. L. Biondi et al., "Increased Plasma Endothelin Levels in Patients with Raynaud's Phenomenon", The New England Journal of Medicine, Apr. 18, 1991, vol. 324, No. 16, pp. 1139-1140.
M. Ishibashi et al., "Plasma Endothelin-1 Levels in Patients with Disseminated Intravascular Coagulation", The New England Journal of Medicine, May 23, 1991, vol. 324, No. 21, pp. 1516-1517.
A. Lerman et al., "Circulating and Tissue Endothelin Immunoreactivity in Advanced Atherosclerosis", The New England Journal of Medicine, Oct. 3, 1991, vol. 325, No. 14, pp. 997-1001.
S. A. Douglas et al., "BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension", Journal of Hypertension, 1994, vol. 12, No. 5, pp. 561-567.
M. Okada et al., "Antihypertensive effects of BQ-123, a selective endothelin ET.sub.A receptor antagonist, in spontaneously hypertensive rats treated with DOCA-salt", European Journal of Pharmacology, 1994, vol. 259, pp. 339-342.
Y. Yokoi et al., "Role of Endogenous Endothelin in Renal Impairment During Acute Liver Rejection in Rats", Transplantation Proceedings, Apr., 1992, vol. 26, No. 2, pp. 904-906.
S. Kivlighn et al., "Effects of BQ-123 on renal function and acute cyclosporine-induced renal dysfunction", Kidney International, 1994, vol. 45, pp. 131-136.
L. Chan et al., "Effect of an endothelin-receptor antagonist on ischemic acute renal failure", Am. J. Physiol. (Renal Fluid Electrolyte Physiol. 35), 1994, vol. 266, pp. F135-F138.
S. Oldroyd et al., "Role for endothelin in the renal responses to radiocontrast media in the rat", Clinical Science, 1994, vol. 87, pp. 427-434.
S. T. Bonvallet et al., "BQ123, an ET.sub.A -receptor antagonist, attenuates hypoxic pulmonary hypertension in rats", Am. J. Physiol. (Heart Circ. Physiol. 35), 1994, vol. 266, pp. H1327-H1331.
H. Ito et al., "Endothelin ET.sub.A Receptor Antagonist Blocks Cardiac Hypertrophy Provoked by Hemodynamic Overload", Ciruclation, May, 1994, vol. 89, No. 5, pp. 2198-2203.
M. Clozel et al., "Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist", Nature, Oct. 21, 1993, vol. 365, pp. 759-761.
S. Itoh et al., "A Novel Endothelin ET.sub.A Receptor Antagonist, BQ-485, and Its Preventive Effect on Experimental Cerebral Vasospasm in Dogs", Biochemical and Biophysical Research Communications, Sep. 15, 1993, vol. 192, No. 2, pp. 969-975.
A. Benigni et al., "A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression", Kidney International, 1993, vol. 44, pp. 440-444.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Endothelin antagonistic substance does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Endothelin antagonistic substance, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Endothelin antagonistic substance will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2203444

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.